```html

Zollinger‑Ellison‑type Gastritis: A Complete Patient Guide

Overview

Zollinger‑Ellison‑type gastritis describes the inflammation of the stomach lining that results from the excessive acid production seen in Zollinger‑Ellison syndrome (ZES). ZES is a rare neuroendocrine tumor (gastrinoma) that secretes large amounts of gastrin, a hormone that stimulates stomach acid. The chronic hyper‑acidic environment damages the mucosa, leading to gastritis and often peptic ulcer disease.

Who it affects: ZES can occur at any age but most often presents in adults between 40 and 60 years. Both genders are affected, with a slight male predominance (≈55%). About 25% of cases are associated with multiple endocrine neoplasia type 1 (MEN‑1), a hereditary condition.

Prevalence: Gastrinomas are rare, occurring in roughly 1–3 per million people worldwide. Because many patients develop ulcers before the gastrinoma is discovered, the exact prevalence of Zollinger‑Ellison‑type gastritis is difficult to calculate, but it is estimated to affect < 0.1% of patients with chronic gastritis.

Symptoms

Symptoms are often severe and atypical compared to ordinary peptic ulcer disease because the acid output can be 10–100 times higher than normal.

• Epigastric pain – burning or gnawing pain that may improve with meals (ulcer) or worsen (gastritis).
• Refractory heartburn – acid reflux that does not respond to over‑the‑counter antacids.
• Diarrhea or steatorrhea – excess acid inactivates pancreatic enzymes, leading to malabsorption.
• Nausea & vomiting – sometimes with blood if an ulcer erodes.
• Weight loss – due to malabsorption, chronic pain, or fear of eating.
• Gastrointestinal bleeding – melena (black, tarry stools) or hematemesis (vomiting blood).
• Fatigue & anemia – from chronic blood loss.
• Upper‑GI ulcer complications – perforation (sudden severe abdominal pain) or obstruction (persistent vomiting, bloating).
• Symptoms of MEN‑1 if present – hyperparathyroidism (kidney stones), pituitary tumors (headaches, vision changes).

Causes and Risk Factors

Underlying cause

Zollinger‑Ellison‑type gastritis is not caused by infection or lifestyle alone; it is secondary to a gastrinoma—a neuroendocrine tumor most often located in the duodenum (≈70%) or pancreas (≈25%). The tumor secretes gastrin, which stimulates parietal cells to produce massive amounts of hydrochloric acid.

Risk factors

• Genetic predisposition – MEN‑1 mutation (15–25% of ZES cases).
• Age – risk rises after age 40.
• Family history of neuroendocrine tumors.
• Chronic H. pylori infection – may coexist and worsen gastritis, though it does not cause ZES.
• Smoking – increases gastrin secretion and may promote tumor growth.

Diagnosis

Because the symptoms overlap with common ulcer disease, a high index of suspicion is needed, especially when ulcers are multiple, refractory, or located distal to the duodenum.

Initial evaluation

• History & physical exam – detailed review of ulcer‑related symptoms, weight change, family history.
• Laboratory tests – fasting serum gastrin level (≥ 1000 pg/mL highly suggestive), calcium & parathyroid hormone (to evaluate MEN‑1).

Confirmatory tests

• Secretin stimulation test – paradoxical rise in gastrin after IV secretin is classic for gastrinoma.
• Imaging
  • Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – most sensitive for locating gastrinomas.
  • CT or MRI abdomen – to assess size, local invasion, and metastasis.
• Upper endoscopy (EGD) – visualizes gastritis, ulcers, and allows biopsy to exclude malignancy.
• pH testing – a 24‑hour intra‑gastric pH <2 confirms hyperacidity.

Treatment Options

Management has two main goals: control acid hypersecretion and treat or remove the gastrinoma.

Acid‑suppression therapy (first line)

• Proton pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole (usually 60–80 mg daily in divided doses). PPIs are the cornerstone; they reduce ulcer healing time and control diarrhea.
• Histamine‑2 receptor antagonists – can be added for breakthrough symptoms but are less effective alone.

Targeted tumor therapy

• Surgical resection – preferred for localized gastrinomas; cure rates up to 70% when the tumor is <2 cm and non‑metastatic.
• Somatostatin analogues (octreotide, lanreotide) – bind somatostatin receptors, suppress gastrin release, and are useful in metastatic disease or when surgery isn’t feasible.
• Targeted systemic therapy – everolimus or sunitinib for progressive metastatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for patients with high receptor expression.
• Chemotherapy – limited role; reserved for high‑grade neuroendocrine carcinoma.

Lifestyle and adjunct measures

• Avoid NSAIDs, aspirin, and alcohol which aggravate gastritis.
• Eat smaller, frequent meals to reduce acid spikes.
• Stay hydrated; oral rehydration solutions help with diarrhea‑related fluid loss.
• Smoking cessation and weight management.

Living with Zollinger‑Ellison‑type Gastritis

Daily management tips

• Medication adherence – take PPIs exactly as prescribed (often 30 minutes before a meal). Do not stop abruptly without a doctor’s order.
• Monitoring – keep a symptom diary (pain, stools, weight). Report new or worsening bleeding, severe abdominal pain, or unexplained weight loss promptly.
• Nutrition
  • Low‑fat, low‑spice diet; avoid citrus, tomato‑based sauces, and carbonated drinks that can increase acid.
  • Consider a dietitian’s help to manage malabsorption and ensure adequate calories, protein, and vitamins (especially B12 and iron).
• Regular follow‑up – at least every 3‑6 months for gastrin levels, endoscopic surveillance, and imaging if the tumor is not resected.
• Vaccinations – patients on high‑dose PPIs have a slightly increased risk of Clostridioides difficile; stay up to date on flu and pneumonia vaccines.

Psychosocial aspects

Living with a rare chronic condition can be stressful. Connect with support groups (e.g., the Neuroendocrine Tumor Research Foundation) and consider counseling if anxiety or depression develops.

Prevention

Because the underlying gastrinoma is not preventable, primary prevention focuses on modifiable risk factors and early detection:

• Screen at‑risk relatives – family members of MEN‑1 patients should undergo genetic counseling and periodic gastrin testing.
• Avoid chronic irritants – limit NSAID use, stop smoking, and moderate alcohol.
• Prompt evaluation of atypical ulcers – ulcers that fail to heal after 8 weeks of standard therapy warrant gastrin measurement.
• Manage H. pylori infection – eradication reduces background gastritis and may lessen ulcer complications.

Complications

If untreated or poorly controlled, Zollinger‑Ellison‑type gastritis can lead to serious health problems:

• Severe peptic ulcer disease – multiple, refractory ulcers; risk of perforation (abdominal emergency).
• Gastrointestinal bleeding – chronic blood loss → iron‑deficiency anemia.
• Malabsorption – chronic diarrhea can cause electrolyte disturbances, weight loss, and deficiencies of fat‑soluble vitamins.
• Gastric outlet obstruction – scarring from chronic ulceration.
• Metastatic gastrinoma – spreads to lymph nodes, liver, or bone in up to 35% of cases, impacting survival.
• Reduced quality of life – persistent pain and nutritional problems.

When to Seek Emergency Care

References

• Mayo Clinic. “Zollinger‑Ellison syndrome.” https://www.mayoclinic.org
• National Institutes of Health – National Institute of Diabetes and Digestive and Kidney Diseases. “Zollinger‑Ellison syndrome.” https://www.niddk.nih.gov
• Cleveland Clinic. “Gastrinomas and Zollinger‑Ellison syndrome.” https://my.clevelandclinic.org
• World Health Organization. “Neuroendocrine Tumors: Overview.” https://www.who.int
• Jonkman J, et al. “Management of Zollinger‑Ellison syndrome: A systematic review.” *Lancet Gastroenterology & Hepatology*, 2022.

```